Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $132.80 USD
Change Today -4.70 / -3.42%
Volume 877.9K
JAZZ On Other Exchanges
As of 8:10 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

Fourth Floor

One Burlington Road

Dublin, 4


Phone: 353 1 634 7800

Fax: 353 1 634 7850

bution by PHE, which also manufactures the product for it. PHE is the company’s sole supplier for Erwinaze. The company is obligated to make tiered royalty payments to PHE based on worldwide net sales of Erwinaze and Erwinase. Defitelio (defibrotide) / defibrotide Defitelio (defibrotide), a product approved in Europe for the treatment of severe hepatic veno-occlusive disease, or VOD, in adults and children undergoing hematopoietic stem cell transplantation, or HSCT, therapy. Defibrotide, the active pharmaceutical ingredient in Defitelio, is the sodium salt of a complex mixture of single-stranded oligodeoxyribonucleotides derived from porcine DNA. During 2014, Defitelio was launched in a number of European countries. The company promotes Defitelio along with Erwinase to many of the same hematology and oncology specialists. The company owns Gentium S.p.A. (Gentium). The company is also assessing the potential for approval of defibrotide in other countries and for development of defibrotide in indications in addition to the treatment of severe VOD. Prialt (ziconotide) Intrathecal Infusion and Other Products The company also commercializes a portfolio of other products, including Prialt. Prialt is an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine. Prialt is the only FDA-approved non-opioid intrathecal analgesic. The company has worldwide rights to Prialt, excluding 34 countries outside of the United States licensed by Eisai Co. Limited, or Eisai, from Elan Pharmaceuticals, Inc. (subsequently acquired by Perrigo Company plc) in 2010. The company supplies Prialt to Eisai. Other products the company sells include various psychiatry products in the United States and products in the oncology, critical care and oncology supportive care therapeutic areas, primarily in markets outside of the United States. Research and Development For the year ended December 31, 2014, the company recorded $85.2 million on research and development expenses. Sales and Marketing The company has commercial operations primarily in the United States and Europe. In the United States, its products are marketed through its commercial teams, including approximately 150 trained, experienced sales professionals who promote Xyrem, Erwinaze and Prialt directly to physicians in specialties appropriate for each product. Outside of the United States, its hematology and oncology sales force has approximately 25 hematology field specialists responsible for promoting Erwinase and Defitelio in approved markets where the company commercializes these products. The company’s commercial activities include marketing-related services, distribution services and commercial support services. Customers and Geographic Areas In the United States, the company’s primary marketed product Xyrem is sold to one specialty pharmacy, ESSDS, which ships Xyrem directly to patients. Erwinaze is sold through an exclusive wholesaler and distributor, Accredo Health Group, Inc., to hospitals. Among the other products it commercializes in the United States, Prialt is sold through an exclusive wholesale distributor and pharmacy to medical facilities, while the others are sold primarily to distributors who distribute the product to pharmacies and hospitals. Outside of the United States, the company distributes Erwinase through Durbin PLC, a U.K.-based wholesaler and distributor, to hospitals and local wholesalers in Europe where it markets Erwinase directly and, in markets where it does not market Erwinase directly, to local distributors and wholesalers in Europe and elsewhere in the world. The company distributes Defitelio primarily through IDIS Limited, or IDIS, a U.K. based distributor, to the European countries where the product has been launched commercially. The company also works with IDIS and a number of local distributors in Europe and elsewhere in the world to distribute defibrotide on a named pat


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JAZZ:US $132.80 USD -4.70

JAZZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $30.52 USD +0.68
Alkermes PLC $59.77 USD -0.71
BioMarin Pharmaceutical Inc $109.93 USD -3.07
Impax Laboratories Inc $38.59 USD +0.39
Sagent Pharmaceuticals Inc $16.07 USD +0.21
View Industry Companies

Industry Analysis


Industry Average

Valuation JAZZ Industry Range
Price/Earnings 33.4x
Price/Sales 6.6x
Price/Book 5.8x
Price/Cash Flow 22.4x
TEV/Sales 4.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at